TCGA-XF-A8HG-01A-11R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.34165572
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.290
- PANCREAS_BETA_CELLS+0.250
- SPERMATOGENESIS+0.220
- BILE_ACID_METABOLISM+0.180
- XENOBIOTIC_METABOLISM+0.100
- PEROXISOME+0.060
- ESTROGEN_RESPONSE_LATE+0.030
- APICAL_SURFACE+0.020
- ESTROGEN_RESPONSE_EARLY+0.000
- CHOLESTEROL_HOMEOSTASIS-0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.510
- TGF_BETA_SIGNALING-0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- IL6_JAK_STAT3_SIGNALING-0.470
- MYC_TARGETS_V1-0.470
- MITOTIC_SPINDLE-0.440
- ALLOGRAFT_REJECTION-0.430
- PI3K_AKT_MTOR_SIGNALING-0.430
- G2M_CHECKPOINT-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG540 | — | — | 0.932 |
| 2 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.928 |
| 3 | TCGA-E7-A7PW-01A-11R-A352-07 | — | — | 0.925 |
| 4 | BS_0Y66ZBWE | low-grade glioma | — | 0.924 |
| 5 | BS_0T17SY47 | low-grade glioma | — | 0.912 |
| 6 | MNG761 | — | — | 0.912 |
| 7 | SRR1356036 | GTEX | — | 0.911 |
| 8 | MNG700 | — | — | 0.911 |
| 9 | BS_QC3XCE6X | low-grade glioma | — | 0.911 |
| 10 | SRR1329334 | GTEX | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |